Latest Nucleosides Stories

2008-12-02 08:00:00

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec.

2008-10-30 09:00:11

The Aplastic Anemia & MDS International has announced that the European Committee for Medicinal Products for Human Use has awarded Vidaza a positive opinion for the treatment of myelodysplastic syndromes patients who are not eligible for stem cell transplants.

2008-10-27 12:00:10

Celgene International has announced that its cancer drug, Vidaza, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia.

2008-09-12 09:00:09

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that it has advanced sapacitabine into Phase 2 development as a second-line treatment for myelodysplastic syndromes (MDS).

2008-08-25 12:01:19

The Moffitt Cancer Center announced today that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug's label.

2008-08-22 12:00:16

The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial.

2008-08-22 06:00:10

Celgene has announced that Vidaza has received expanded FDA approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes.

2008-08-21 12:01:28

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the U.S.

2008-08-05 06:00:46

Clinical Data, Inc. (NASDAQ:CLDA) today announced the acquisition of Adenosine Therapeutics, L.L.C., a developer of drug products based on its extensive portfolio of composition of matter and method of use patents relating to selective adenosine receptor modulators.

2008-07-28 09:01:47

NEW YORK, July 28 /PRNewswire/ -- AIM Pharmakon, Inc. (API), a New York-based company, announced today the introduction of the next generation of high-level cardiovascular health and longevity products starting with Aim Endurance(TM), a new premium quality liquid concentrate.

Word of the Day
  • A trick or prank.
The word 'shavie' is related to 'shave'.